Trial Profile
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Prednisone
- Indications Pneumonitis
- Focus Therapeutic Use
- 01 Aug 2023 Results published in the International Journal of Radiation Oncology, Biology, Physics
- 21 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 21 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.